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interference  in a tissue-speci c manner. 10 
In addition, more and more 7 y models for 
human diseases are becoming available in 
which not only the involvements of genes 
can be tested but also the e/ ect of chemi-
cal compounds and drugs. 
 So what can be expected for the  eld of 
podocyte biology? As with all model sys-
tems, there are and will be limitations to 
the transfer of knowledge from nephro-
cyte to podocyte. However, the identi ca-
tion of the  Drosophila nephrocyte o/ ers 
the opportunity to develop  in vivo assays 
that can be exploited for single-gene anal-
ysis or genome-wide approaches. Such 
assays could help to  nd novel players and 
mechanisms for complex podocyte path-
ways such as slit diaphragm assembly or 
 ltration in health and disease — not bad 
for a simple fruit 7 y. 
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 The ubiquitin-proteasome 
pathway and IgA nephropathy: 
a novel link? 
 Sydney C.W.  Tang 1 and  Kar Neng  Lai 1 
 Proteasomal degradation of intracellular proteins facilitates the 
recognition of foreign proteins through interactions with major 
histocompatibility complex molecules presented to T cells. Interferon-  
enhances the efficiency of this antigen presentation process by inducing 
a switch of proteasome to immunoproteasome catalytic subunits. The 
finding that immunoproteasomes are upregulated in IgA nephropathy 
may prompt further exploration of the role and mechanism of 
proteasome activation and intensify the quest for infectious agents that 
may induce IgA nephritis . 
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polypeptide cofactor that is evolutionarily 
conserved from yeast to humans. The 
protein was so named to re7 ect its wide-
spread tissue distribution across species. 
  e UPP employs the concerted actions 
of a succession of speci c enzymes (E1, 
E2, and E3) that sequentially conjugate 
chains of Ub onto proteins that are des-
tined for degradation via a three-step 
process of Ub activation and substrate 
recognition. 1  is tagging process, known 
as ubiquitination, is a prelude to the rec-
ognition and  nal execution of the pro-
tein destruction command by the 26S 
proteasome. 
  e 26S proteasome is a large subcel-
lular organelle found in the nucleus and 
the cytosol of all cells. It constitutes 
approximately 1 – 2 % of cell mass and 
provides the site for adenosine triphos-
phate-dependent  degradation of Ub-
tagged proteins. 2  e 26S proteasome is 
essentially a hollow cylindrical particle 
made up of a 20S catalytic component 
and a 19S regulatory unit.  e central 20S 
complex is made up of four heptameric 
protein rings assembled like four dough-
nuts comprising two identical outer 
  -rings and two identical inner   -rings, 
each containing seven subunits,   1 –  7 
and   1 –  7, respectively. The   1,   2, 
 Body proteins were once viewed as struc-
turally static, while dietary proteins were 
believed to function primarily as sources 
of energy. With the discovery of the lyso-
some, Greek for  ‘ digestive body, ’ more than 
half a century ago, it had been assumed 
that cellular proteins were degraded within 
this organelle until lysosomal inhibitors 
were found to be ine/ ective in preventing 
basal protein breakdown. In the past two 
decades, the focus in this  eld has shiN ed 
to the ubiquitin-proteasome pathway 
(UPP), a tightly regulated system that 
degrades intracellular proteins to facilitate 
cellular adaptations to new physiologic 
conditions. Indeed, the discovery of ubiq-
uitin and the understanding of its role in 
protein degradation led to the awarding of 
the 2004 Nobel Prize in Chemistry to co-
recipients Avram Hershko, Aaron Ciech-
anover, and Irwin Rose. 
 Ubiquitin (Ub) is an abundant 9-
kilodalton or 76-amino acid cellular 
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and    5 subunits harbor the active 
proteolytic sites that are positioned 
toward the hollow center of the cylinder 
structure and possess postglutamyl-, 
trypsin-, and chymotrypsin-like hydro-
lytic activities, respectively. The two 
  -rings sandwiching the   -rings (  7 –  7 –
  7 –  7   arrangement) surround a narrow, 
central pore for substrate entry and prod-
uct exit.  e 19S complex caps the   -ring 
on each side and acts as a gatekeeper to 
allow passage only of Ub-tagged proteins 
into the proteasome, thus preventing 
nonspeci c destruction of cell proteins 
( Figure 1 ). 
 By virtue of its ability to handle vast 
amounts of intracellular proteins, the UPP 
forms an integral component in numer-
ous cellular processes, including cell-cycle 
regulation, induction of the in7 ammatory 
response, and antigen presentation. Not 
surprisingly, aberrations of the UPP have 
been implicated in many disease states, 
including infection, carcinogenesis, ure-
mic muscle wasting, and antibody-medi-
ated autoimmune disorders. 3 Here, we 
focus on the role of the UPP in immune 
surveillance and regulation. 
 Many transcriptional factors undergo 
ubiquitination followed by proteasomal 
degradation. One relevant example is the 
regulation of nuclear factor-  B (NF-  B) 
activation. This proinflammatory tran-
scriptional activator is normally secluded 
outside the cell nucleus through its asso-
ciation with I  B. Inflammatory signals 
activate phosphorylation of I  B, which 
becomes recognized by the E3   -trans-
ducin repeat-containing protein, a member 
of the Ub conjugation enzymatic cascade. 
I  B is then ubiquitinated and rapidly 
degraded, releasing the NF-  B complex 
that translocates into the nucleus to trigger 
downstream in7 ammatory response. 4 
 Proteasomal breakdown of intracellular 
proteins enables the immune system to 
detect foreign proteins through interac-
tions with major histocompatibility com-
plex (MHC) class I molecules that bind 
oligopeptides that are 8 – 10 residues long. 
Most proteasomal cleavage products are 
too long and must be trimmed at the N 
terminus in the endoplasmic reticulum by 
aminopeptidases aN er they are taken up 
by a speci c peptide transport system, 
called transporter associated with antigen 
processing (TAP). Endoplasmic reticulum 
aminopeptidase 1 (ERAP1) then tailors 
these peptides to the precise length for 
binding to MHC class I molecules before 
they are delivered to the cell surface for 
presentation to cytotoxic CD8   +   lym-
phocytes. 5 Non-native epitopes presented 
on the cell surface, such as those derived 
from viruses or cancerous cells, are recog-
nized by cytotoxic T cells, which rapidly 
destroy the presenting cell. 
 To enhance the efficiency of antigen 
presentation during inflammation, 
immune cells develop several adaptive 
mechanisms. Interferon-  (IFN-  ), pro-
duced mainly by T-helper 1 (  1) cells, 
cytotoxic T cells, dendritic cells, and natu-
ral killer   cells, is a prominent cytokine 
featured in many in7 ammatory condi-
tions. In response to IFN-  challenge, 
immune cells undergo a switch to express 
novel types of proteasomes, termed 
immunoproteasomes (iPSs), which play a 
major role in augmenting the e.  ciency of 
MHC class I presentation. 6  e iPSs di/ er 
because they contain three novel pepti-
dase subunits, LMP2, MECL-1, and 
LMP5, that replace their constitutive 
counterparts   1,   2, and   5, respectively. 
These specialized peptidases, together 
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 Figure 1  |   Proteasome structure and its role in intracellular protein degradation and antigen 
processing. Ubiquitinated proteins destined for degradation are recognized by the 19S regulatory 
unit, which allows their passage to the inside of the hollow cylindrical 20S central core, where 
proteolytic subunits of the   -ring facing internally cleave the protein into peptides. These peptides 
are taken up by the transporter associated with antigen processing (TAP) of the endoplasmic 
reticulum (ER), where the ERAP1 peptide-trimming enzyme processes them into oligopeptides 
of the appropriate residue length to bind major histocompatibility complex (MHC) class I 
molecules. When challenged by interferon-  (IFN-  ), the antigen-presenting cell (APC) expresses 
immunoproteasomes (iPS) in which the constitutive   -catalytic sites of the quiescent proteasome 
undergo a switch to express more potent peptidases. At the same time, IFN-  upregulates 
(indicated by plus signs) TAP, ERAP1, and MHC expression. Together, these changes result in an 
expansion of proteolytic cleavage products, thereby enhancing antigen presentation by MHC 
molecules. Non-self epitopes are presented on the cell surface to cytotoxic T cells, which rapidly 
destroy the cell. 
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with the superinduction of a special pro-
teasome-activating complex, PA28, exhibit 
enhanced protein cleavage properties that 
expand the number of products capable 
of binding to MHC class I molecules and 
acting as antigenic precursors. In addi-
tion, IFN-  upregulates the expression of 
the TAP transporter, the ERAP1 peptide-
trimming enzyme, and MHC molecules. 
Collectively, these adaptive responses 
elevate host defense to new heights 
(Figure 1). Mice that lack iPS subunits were 
unable to e.  ciently process and present 
CD8   +   T-cell epitopes. Apparently, antigen 
processing constitutively functions well 
below maximal levels until activation of 
the host ’ s defenses is necessary. Switching 
from proteasome to IFN-  -inducible iPS, 
therefore, allows more e.  cient antigen 
presentation and facilitates recognition of 
foreign cells and their rapid elimination 
under a variety of conditions. 
 IgA nephropathy (IgAN) is a disease 
arising from structural aberrations, such 
as anomalous galactosylation of the IgA 
molecule, which becomes trapped in the 
glomerular mesangium and induces vari-
able degrees of hematuria, proteinuria, and 
progressive renal failure. 7  e typical exac-
erbation of hematuria in some patients 
following a mucosal infection suggests the 
participation of infectious agents in dis-
ease pathogenesis. In agreement with this 
notion, Coppo  et al. 8 (this issue) report a 
signi cant switch from proteasome to iPS 
expression, reflected by increased iPS /
 proteasome catalytic subunit ratios, in 
peripheral blood mononuclear cells of 
patients with IgAN. Understandably, this 
phenotypic switch, along with activation 
of NF-  B p50 and p65 , will augment the 
e.  ciency of MHC class I antigen process-
ing and presentation to reactive T cells. 
More importantly, the authors show that 
the pattern of this switch was completely 
di/ erent from that of control subjects with 
respiratory or gastrointestinal infections 
without renal disease, or subjects with idi-
opathic nephrotic syndrome, highlighting 
the probable speci city of the proteasomal 
switch in IgAN. Of the three active cata-
lytic iPS subunits, only LMP7 correlated 
with proteinuria levels in IgAN, but not in 
other nephrotic states. 
 Indeed, participation of the proteasome 
or its switching to iPS is being increasingly 
recognized during viral infections. iPSs 
were induced in hepatocytes during hepa-
titis C infection. E.  cient antigen presen-
tation required the structural components 
of iPSs during hepatitis B infection. 9 Dur-
ing fungal infection, there was a switch of 
  1 and   5 to their LMP2 and LMP7 coun-
terparts, 10 respectively, whereas in HIV 
infection, these critical immune processes 
were attenuated. Infection of mice with 
lymphocytic choriomeningitis virus or 
 Listeria monocytogenes led to a near-com-
plete replacement of proteasomes by iPSs 
in the liver. 11 The putative enhancing 
e/ ect of iPS switching on T-cell responses, 
however, was recently challenged by Nuss-
baum  et al. , 12 who demonstrated similar 
virus-speci c CD8   +   T-cell responses and 
viral clearance rates between wild-type 
and LMP2   −  /  −   mice . 
 Given the prominent role of proteaso-
mal switching during various viral infec-
tions, Coppo  et al. 8 postulated that the iPS 
upregulation observed in IgAN may 
re7 ect a host response to immune chal-
lenges, possibly from viral infections that 
trigger IFN-  release. Such a contention is 
in agreement with the activation of the  
Th1 lymphocyte subset leading to 
increased release of IFN-  , among other 
cytokines, in IgAN. 13  ere are, however, 
certain caveats to their observation.  e 
identity of this infectious agent remains 
an enigma, and evidence of an infective 
pathogenetic origin of IgAN as suggested 
by iPS induction is only circumstantial. 
  e adaptive signi cance of a switch to 
only LMP7 and MECL-1, but not LMP2, 
remains to be explored. If viral infection 
were indeed a culprit, presumably more 
than one pathogen would be involved, in 
view of the diverse nature of IgAN.  en, 
it remains to be explained why only a sin-
gle pattern of switching was observed, 
given that di/ erent pathogens are known 
to induce di/ erent iPS subunits . Although 
correlation with proteinuria is relevant, 
the reason behind the exclusive participa-
tion of LMP7 is as yet unclear. Finally, 
whether proteasomal switching in periph-
eral blood mononuclear cells can be 
extrapolated to B cells that maintain a 
continuous mucosa-bone marrow cross-
talk in IgAN 14 remains to be explored. 
 Nonetheless, the novel  nding of protea-
somal switching to iPSs in peripheral 
blood mononuclear cells in IgAN has shed 
new light on the pathogenesis of IgAN and 
provided new evidence for immune acti-
vation in IgAN. Further research is neces-
sary to carefully characterize the speci city 
and signaling mechanisms underlying this 
phenotypic switch and how this might 
translate into nephritis. Clinical trials 
examining the therapeutic potential of 
proteasome inhibitors lie further away. 
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